Document is current
Any future updates will be listed below
-
Authors
Horvat-Menih, Ines
McLean, Mary A
Birchall, Jonathan
Zamora Morales, Maria Jesus
Wylot, Marta
Ursprung, Stephan
Woitek, Ramona
Serrao, Eva
Grimmer, Ashley
Latimer, Elizabeth
Khan, Alixander S
Priest, Andrew N
Gill, Andrew B
Kaggie, Joshua D
Graves, Martin J
Barrett, Tristan
Wason, James MS
Mossop, Helen
Thomas, Martin
Said, Sulekha
Warren, Anne Y
Fife, Kate
Eisen, Tim
Matakidou, Athena
Ince, Will
O’Carrigan, Brent
Jones, James O
Welsh, Sarah J
Mitchell, Thomas J
Armitage, James N
Riddick, Antony CP
Stewart, Grant D
Gallagher, Ferdia A
-
Clinical Trials BETA
Clinical trials referenced in this document:
nct03741426 at ClinicalTrials.govDocuments that mention this clinical trial
Evaluating the metabolic effects of neoadjuvant treatment in clear cell renal cell carcinoma using hyperpolarized [1-13 C]pyruvate MRI
https://doi.org/10.1007/s00261-025-05313-z
-
Funding
Funding for this research was provided by:
Cancer Research UK (C19212/A27150, C19212/A27150)
Mark Foundation For Cancer Research (RG95043, RG95043)
Cancer Research UK Cambridge Institute, University of Cambridge (C9685/A25177, C9685/A25177)
NIHR Cambridge Biomedical Research Centre (BRC-1215-20014, BRC-1215-20014)
National Cancer Imaging Translational Accelerator (C42780/A27066, C42780/A27066)
- License Information
-
More Information
Article History
Received: 20 August 2025
Revised: 24 October 2025
Accepted: 17 November 2025
First Online: 10 December 2025
Declarations
:
: G.D.S. has received educational grants from Pfizer, AstraZeneca, and Intuitive Surgical; consultancy fees from Pfizer, MSD, EUSA Pharma, and CMR Surgical; travel expenses from MSD and Pfizer; speaker fees from Pfizer; clinical lead (urology) National Kidney Cancer Audit and Topic Advisor for the NICE kidney cancer guideline. S.J.W. is a founder and director of Pinto Medical Consultancy. F.A.G. and J.D.K. have research grants from GlaxoSmithKline and AstraZeneca and research support from GE Healthcare. F.A.G. has consulted for AstraZeneca on behalf of the University of Cambridge.
